1. Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia
- Author
-
Lucía Fernández, Manoj Garg, H. Phillip Koeffler, Lee Yung Shih, Qiao-Yang Sun, Yan-Yi Jiang, Der Cherng Liang, Masashi Sanada, Yasunobu Nagata, Xin-Yi Loh, Wenwen Chien, Kar Tong Tan, De-Chen Lin, Hema Preethi, Hagop M. Kantarjian, Henry Yang, Li Zhen Liu, Ling-Wen Ding, Su Lin Lim, Steven M. Kornblau, Anand Mayakonda Thippeswamy, Jin Fen Xiao, Vikas Madan, Norihiko Kawamata, Seishi Ogawa, Liang Xu, Allen Eng Juh Yeoh, Michael Lill, and Satoru Miyano
- Subjects
0301 basic medicine ,Male ,Cancer Research ,ARID1A ,DNA Mutational Analysis ,Bioinformatics ,Receptor tyrosine kinase ,Mice ,2.1 Biological and endogenous factors ,Aetiology ,Child ,Cancer ,Pediatric ,biology ,Blotting ,High-Throughput Nucleotide Sequencing ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Oncology ,Child, Preschool ,Female ,Tyrosine kinase ,Western ,Biotechnology ,Pediatric Research Initiative ,Adolescent ,Pediatric Cancer ,Childhood Leukemia ,Blotting, Western ,Oncology and Carcinogenesis ,Article ,03 medical and health sciences ,Rare Diseases ,Clinical Research ,medicine ,Genetics ,Animals ,Humans ,Epigenetics ,Oncology & Carcinogenesis ,Preschool ,Transcription factor ,Infant ,medicine.disease ,030104 developmental biology ,Good Health and Well Being ,CTCF ,Mutation ,biology.protein - Abstract
Current standard of care for patients with pediatric acute lymphoblastic leukemia (ALL) is mainly effective, with high remission rates after treatment. However, the genetic perturbations that give rise to this disease remain largely undefined, limiting the ability to address resistant tumors or develop less toxic targeted therapies. Here, we report the use of next-generation sequencing to interrogate the genetic and pathogenic mechanisms of 240 pediatric ALL cases with their matched remission samples. Commonly mutated genes fell into several categories, including RAS/receptor tyrosine kinases, epigenetic regulators, transcription factors involved in lineage commitment, and the p53/cell-cycle pathway. Unique recurrent mutational hotspots were observed in epigenetic regulators CREBBP (R1446C/H), WHSC1 (E1099K), and the tyrosine kinase FLT3 (K663R, N676K). The mutant WHSC1 was established as a gain-of-function oncogene, while the epigenetic regulator ARID1A and transcription factor CTCF were functionally identified as potential tumor suppressors. Analysis of 28 diagnosis/relapse trio patients plus 10 relapse cases revealed four evolutionary paths and uncovered the ordering of acquisition of mutations in these patients. This study provides a detailed mutational portrait of pediatric ALL and gives insights into the molecular pathogenesis of this disease. Cancer Res; 77(2); 390–400. ©2016 AACR.
- Published
- 2017